Galectin Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Galectin Therapeutics

15/05/2023 13:51

* Galectin Therapeutics Inc  GALT.OQ  reported a quarterly
adjusted loss of 19 cents​​ per share for the quarter ended in
March. The lone analyst forecast for the quarter was for a loss
of 21 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Galectin Therapeutics Inc's reported EPS for the quarter
was a
loss of 19 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Galectin Therapeutics Inc shares had fallen by 19.5% this
quarter and gained 49.6% so far this year.
    * The company reported a quarterly loss of $11.26 million.
    * Wall Street's median 12-month price target for Galectin
Therapeutics Inc is $11.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 12:51 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.21          -0.19          Beat
 Dec. 31 2022      -0.17          -0.18          Missed
 Sep. 30 2022      -0.20          -0.14          Beat
 Jun. 30 2022      -0.19          -0.16          Beat